2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Immunology, White Blood Cell Disorders, Lymphoid Malignancies, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

4898 A primary patient-derived xenograft of treatment-naïve TP53-CHIP reveals radioresistance of the mutant clone and radiosensitivity of non-mutant cells

Mareike Peters, Sergiu Pasca2, Teodora Supeanu3, Jiajun Xie4, Hamzah Kharabsheh5, Bogdan Paun6, Lukasz P. Gondek, MD, PhD7, Gabriel Ghiaur, MD, PhD8
1 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
2 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
3 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
4 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
5 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
6 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
7 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
8 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States

Myeloid neoplasms with TP53 mutations (TP53-MNs) carry a dismal prognosis. Clonal hematopoiesis of indeterminate potential with TP53 mutations (TP53-CHIP) has a very high risk to evolve into TP53-MNs under radiation or genotoxic therapy. TP53-CHIP is understood as a dysfunction of the mutant clone, and the non-mutant hematopoiesis is presumed healthy. Data emerging from DNMT3A-CHIP suggest that non-mutant hematopoiesis may be compromised in CHIP. Here, we test how the mutant and non-mutant hematopoietic clones from individuals with treatment-naïve, low variant-allele-frequency (VAF) TP53-CHIP respond to radiation exposure, making use of a newly developed patient-derived xenograft model (PDX).

In hematologically healthy adults undergoing hip replacement, 2.8% (6/211) carried treatment-naïve, low VAF TP53-CHIP (range 1.1-3.7%). To separate mutant from non-mutant progenitor function, we performed colony-forming unit (CFU) assay with single-colony Sanger genotyping (n=3 TP53-CHIP). Mutant progenitors had monoallelic TP53 mutations and were present among colonies at their bulk frequency (mutant CFU was 2x bulk VAF), indicating no clonogenic advantage. Yet, TP53-CHIP marrows had 54% more progenitors than age-/sex-matched controls (median [range]: 145 [125-215] vs 94 [91-115] CFU/104 CD34+, p=0.029). As the mutant clone made up only 2.4-4.5% of colonies (median 3.9%), the increased progenitor frequency was carried by the non-mutant, not the mutant, fraction.

To establish a PDX, 1x105 CD34+ cells were transplanted into conditioned NSG mice. At baseline the PDX reproduced the patient immunophenotype, with robust engraftment levels (median [IQR]: CHIP: 23.3% [11-45], CTR: 34.7% [15-63], p=0.596), and no lineage bias. Across 3 donors the TP53 clone was maintained in the bulk graft (post-engraftment 3.1, 2.1 and 1.5% vs 3.7, 1.9 and 1.2% pre-transplant, respectively), and the increased clonogenicity of progenitors persisted (3.5- and 2.7-fold each above its matched control, in 2 experiments).

To determine how radiation acts on mutant and non-mutant compartments, we irradiated engrafted mice (2 Gy) and analyzed them 4 weeks later. We measured the frequency of mutant cells by NGS and total cellularity per femur by Hemavet. The absolute number of mutant cells was unchanged by radiation while non-mutant cells fell 1.89-fold, leading to 1.8- and 6.5-fold rise in VAF. After radiation, the mutant clone was enriched among surviving colony-forming progenitors, reaching 32% and 44% of CFUs, exceeding the expected (2x bulk VAF) 5.5% and 26.2% (p<0.005). We detected only one biallelic (LOH) TP53 clone. Thus, for the most part, the clones remained heterozygous, suggesting that resistance to radiation did not require biallelic loss. By analyzing human cells isolated from the TP53-CHIP PDX, we found that the TP53-CHIP graft lost clonogenicity at 4 weeks (2.5-fold per CD34+, 17.7-fold per hCD45+) whereas its matched control did not. Given the low VAF, these findings imply that the non-mutant compartment in TP53-CHIP is itself radiosensitive compared to normal, non-CHIP progenitors.

To assess if the non-mutant compartment can be protected, we tested trilaciclib, a CDK4/6 inhibitor shown to limit chemotherapy-induced TP53-CHIP expansion. In healthy CD34+ HSPCs, trilaciclib pretreatment (24h before 2 Gy) improved survival (42% vs 25%), with in vivo studies ongoing.

In conclusion, our data uncover an asymmetry within treatment-naïve TP53-CHIP: the mutant clone is preserved while the surrounding non-mutant compartment is preferentially depleted compared not only to mutant hematopoiesis but also to normal, non-CHIP progenitors. Thus, the apparent clonal expansion reflects loss of the non-mutant cells as much as mutant survival. These individuals may thus be more vulnerable to radiation-driven progression than the mutant clone alone predicts. This primary PDX uniquely enables functional study of both compartments.

Mareike Peters: No relevant conflicts of interest to declare.